Article
Medicine, Research & Experimental
Paulina Maria Reyes-Mata, Argelia Esperanza Rojas-Mayorquin, Lucrecia Carrera-Quintanar, Celia Gonzalez-Castillo, Mario Alberto Mireles-Ramirez, Jose de Jesus Guerrero-Garcia, Daniel Ortuno-Sahagun
Summary: This study aimed to investigate the serum levels of Pleiotrophin (PTN) in patients with Multiple Sclerosis (MS). The results showed that PTN serum levels were significantly higher in RRMS patients compared to the healthy control group, and were associated with sex, body mass index (BMI), and IFN-beta treatment.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Article
Neurosciences
Charidimos Tsagkas, Katrin Parmar, Simon Pezold, Christian Barro, Mallar M. Chakravarty, Laura Gaetano, Yvonne Naegelin, Michael Amann, Athina Papadopoulou, Jens Wuerfel, Ludwig Kappos, Jens Kuhle, Till Sprenger, Cristina Granziera, Stefano Magon
Summary: Distinct patterns of volume loss over time were found in different central nervous system structures in multiple sclerosis (MS) patients, independent of disease duration and lesion-load but associated with sNfL levels, relapse rates, and clinical worsening. This suggests a need for a more biologic classification of MS subtypes incorporating volumetric and body-fluid markers.
HUMAN BRAIN MAPPING
(2021)
Review
Pharmacology & Pharmacy
Carmen Rodriguez-Cueto, Laura Garcia-Toscano, Irene Santos-Garcia, Marta Gomez-Almeria, Claudia Gonzalo-Consuegra, Francisco Espejo-Porras, Javier Fernandez-Ruiz, Eva de Lago
Summary: Cannabinoids have therapeutic effects by targeting different elements of the endocannabinoid system, with potential as neuroprotective agents in ALS. The focus is on the activation of the CB2 receptor to limit glial reactivity, and there is a need for clinical trials to confirm the potential of cannabinoid-based medicines in ALS.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Article
Clinical Neurology
Thomas F. Scott, Ray Su, Kuangnan Xiong, Arman Altincatal, Carmen Castrillo-Viguera, Maria L. Naylor
Summary: Results from separate matching comparisons of phase III clinical trials and extension studies suggest that peginterferon beta-1a 125 mcg Q2W may provide better clinical outcomes than GA (20 mg/ml QD or 40 mg/ml TIW).
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2021)
Review
Rheumatology
Nina N. Hofmann, Robert A. Ambuehl, Suzana Jordan, Oliver Distler
Summary: This article reviews the treatment effectiveness and adverse events of calcineurin inhibitors (CNIs) in patients with systemic sclerosis (SSc). The results show potential effectiveness of CsA in improving skin and pulmonary fibrosis, but the evidence level of the identified studies is low. Renal toxicity of CNIs is a common adverse event that needs to be considered in future research.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Rina Aharoni, Raya Eilam, Shaul Lerner, Efrat Shavit-Stein, Amir Dori, Joab Chapman, Ruth Arnon
Summary: The study suggests that in MOG 35-55 induced EAE, neuronal loss is not due to apoptotic cell death but rather axonal damage present in the early stages of the disease. Elevated interstitial glutamate concentrations in the cerebrospinal fluid indicate the involvement of glutamate excess in the damage processes inflicted by this disease. Treatment with GA significantly reduces pathological manifestations such as apoptotic cell death, NFL leakage, histological tissue damage, and glutamate excess, demonstrating the neuroprotective effects of this therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Carmen-Adella Sirbu, Ruxandra Georgescu, Florentina Cristina Plesa, Alina Paunescu, Monica Marilena Tantu, Alina Crenguta Nicolae, Ionut Caloianu, Marian Mitrica
Summary: This review provides an overview of the evidence of the role of cannabinoids in treating symptoms related to MS and highlights the need for further research. Despite some clinical trials showing the efficacy of cannabinoids in alleviating MS-related symptoms, there are still areas of uncertainty. Considering their various mechanisms of action and good tolerability, cannabinoids remain an interesting therapy for MS-related symptoms.
AMERICAN JOURNAL OF THERAPEUTICS
(2023)
Article
Multidisciplinary Sciences
Ioana S. Barac, Vitalie Vacaras, Mihaela Iancu, Dafin F. Muresanu, Lucia M. Procopciuc
Summary: This study aimed to test the association between interferon and long-chain synthesis gene polymorphisms with multiple sclerosis (MS) patients. The results showed a significant correlation between serum levels of IL-27 and IL-23 with gene polymorphisms in RRMS patients.
Review
Biochemistry & Molecular Biology
Teresa Gianferrara, Eleonora Cescon, Ilenia Grieco, Giampiero Spalluto, Stephanie Federico
Summary: GSK-3 beta activity is closely related to neuroinflammation and neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This review provides a comprehensive overview of the structure, regulation, and implications of GSK-3 beta in the context of neuroinflammation and neurodegeneration. The potential of GSK-3 beta inhibitors as a therapeutic approach is also discussed.
CURRENT MEDICINAL CHEMISTRY
(2022)
Review
Chemistry, Medicinal
Mohan Gupta, Avinash Kumar, Madhwi Ojha, Shabana Kausar Khan, Sumitra Nain
Summary: Alzheimer's disease is an irreversible, progressive, and complex brain disorder. Recent studies have shown that small organic molecules containing heterocycles such as thiazole, pyridine, dihydropyridine, piperidine, pyrrolidine, pyrazole, quinoline, etc., have shown promising results as anti-Alzheimer's agents.
MINI-REVIEWS IN MEDICINAL CHEMISTRY
(2023)
Article
Clinical Neurology
Mathilde Lefort, Sandra Vukusic, Romain Casey, Gilles Edan, Emmanuelle Leray
Summary: Early treatment initiation has a significant impact on disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), reducing the risk of disability development, particularly in older patients.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Review
Neurosciences
Amir Valizadeh, Mohammad Reza Fattahi, Maryam Sadeghi, Mehrnush Saghab Torbati, Mohammad Ali Sahraian, Amir Reza Azimi
Summary: The study found that DMTs can reduce the number and volume of T1 hypointense lesions in MS patients, but these findings need to be interpreted cautiously due to high heterogeneity values. The results suggest that DMTs have a certain impact on the progression of the disease in MS patients.
CNS NEUROSCIENCE & THERAPEUTICS
(2022)
Article
Urology & Nephrology
Hong-Guang He, Yi-Yun Huang, Qin-Qing Liang, Qiu-Rong Ye, An-Dong Li, Kun Ye, Qiu-Xia Wu, Yan-Wu You
Summary: This study compared the prognosis differences between two regimens in patients with IMN combined with FSGS lesions. The results showed that compared to CTX therapy, CNIs therapy had poorer initial treatment outcomes, higher risk of renal functional decline and higher relapse rate.
Article
Biochemistry & Molecular Biology
Maria Paulina Reyes-Mata, Mario Alberto Mireles-Ramirez, Christian Grinan-Ferre, Merce Pallas, Lenin Pavon, Jose de Jesus Guerrero-Garcia, Daniel Ortuno-Sahagun
Summary: Multiple sclerosis is a chronic disease characterized by an autoimmune attack on axonal myelin sheaths in the central nervous system. Epigenetics has been studied as a research topic in the search for biomarkers and treatment targets for this disease. This study examined epigenetic marks in Peripheral Blood Mononuclear Cells (PBMCs) from MS patients treated with IFN-beta and GA or untreated, as well as healthy controls, and found that DNA methylation decreased in treated patients and correlated with clinical variables. However, no biomarker has been identified to predict treatment response before initiation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Clinical Neurology
Martin Valis, Zbysek Pavelek, Michal Novotny, Blanka Klimova, Jana Sarlakova, Simona Haluskova, Marek Peterka, Ivana Stetkarova, Pavel Stourac, Jan Mares, Pavel Hradilek, Radek Ampapa, Marta Vachova, Eva Recmanova, Eva Meluzinova
Summary: This study analyzed the characteristics and treatment of pediatric patients with multiple sclerosis. The results showed that these patients usually start disease-modifying drug treatment at the age of 15.89, with moderate and mild relapses being common. Moreover, the first-choice treatment is similar to that of adult patients, but low efficacy or lack of tolerance may lead to treatment discontinuation in children.
FRONTIERS IN NEUROLOGY
(2022)
